Trial Profile
SSAT058: A phase IV, open-label, multi centre pilot study to assess changes in cerebral function parameters in patients without perceived Central Nervous System (CNS) symptoms when switched from tenofovir/emtricitabine/efavirenz (Atripla) to a fixed dose combination of tenofovir/emtricitabine/rilpivirine (Eviplera)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/rilpivirine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- 15 Sep 2017 Status changed from active, no longer recruiting to completed.
- 26 Jul 2017 Results presented at the 9th International AIDS Society Conference on HIV Science
- 28 Nov 2016 Status changed from recruiting to active, no longer recruiting.